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OBJECTIVEdTo determine variables associated with glycemic and body weight responses
when adding exenatide to basal insulin–treated type 2 diabetes.
RESEARCH DESIGN AND METHODSdExploratory subgroup analyses based on base-
line A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo,
added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo).
RESULTSdExenatide participants had greater A1C reductions compared with optimized in-
sulin glargine alone, irrespective of baseline A1C (P, 0.001). Exenatide participants with longer
diabetes duration and those with lower BMI had greater A1C reductions (P , 0.01). Exenatide
participants lost more weight, regardless of baseline A1C or BMI (P , 0.05). Exenatide partic-
ipants with longer diabetes duration lost the most weight (P , 0.001).
CONCLUSIONSdExenatide added to optimized basal insulin was associated with im-
proved glycemic control and weight loss, irrespective of baseline A1C, diabetes duration,
and BMI. Changes were evident in modestly obese patients and in those with longer diabetes
duration.
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T he combined use of glucagon-likepeptide 1 (GLP-1) receptor agonistsand insulin is of growing clinical
interest (1–6), and the combined use
of insulin glargine with exenatide is now
approved in the U.S. In this recent study,
exenatide twice daily added to optimized
titration of glargine resulted in greater
A1C improvements with weight loss and
lesser increase in insulin dose than placebo
plus optimized glargine (5). The current
exploratory post hoc analysis assessed the
relationship of baseline A1C, duration of
diabetes, and BMI with glucose control,
body weight changes, and insulin doses
in that study.
RESEARCH DESIGN AND
METHODSdA full study description
has been published (5). The study was ap-
proved by institutional review boards in ac-
cordance with the Declaration of Helsinki.
Participants were on$20 units/day of
insulin glargine, alone or plus metformin
and/or pioglitazone, with A1C 7.1–10.5%
and BMI #45 kg/m2. At randomization, if
A1C.8.0%, insulin glargine dose contin-
ued unchanged, but if A1C #8.0%, the
dose was decreased by 20%. After 5 weeks,
participants began weekly structured insu-
lin titrations to achieve a fasting glucose
,100mg/dL (7) guided by self-monitoring
of blood glucose.
Subgroups
Participant subgroups included baseline
A1C (#8 and .8%), duration of disease
(,9, 9–15, and.15 years), and baseline
BMI (,30, 30–36, and .36 kg/m2).
Statistical methods
Mixed models with repeated measures
similar to the original analyses (5) were fit-
ted separately to subgroups.
RESULTSdOut of 261 randomized par-
ticipants, 2 discontinued without receiving
study medication, leaving 137 exenatide
and 122 placebo participants to be in-
cluded in the intent-to-treat analysis. Base-
line characteristics were similar between
the two treatment groups (5).
Glycemic control
Both exenatide and placebo participants
had significant A1C reductions regardless
of baseline A1C, duration of diabetes, or
baseline BMI (Supplementary Table 1 and
Supplementary Fig. 1). Exenatide partici-
pants had significantly greater A1C reduc-
tions compared with placebo participants
at end point regardless of baseline A1C
(least square [LS] mean difference, A1C
#8%: 20.52%; A1C .8%: 20.75%;
P , 0.001). Exenatide participants with
9–15 and .15 years of diabetes had
greater A1C reductions compared with
placebo participants at end point (LS
mean difference,20.78 and20.82%, re-
spectively; P , 0.001); exenatide partic-
ipants with ,9 years of diabetes had
lesser A1C reduction (LS mean differ-
ence, 20.31%; P = 0.124). Exenatide
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participants with ,30 and 30–36 kg/m2
BMI had greater reductions in A1C com-
pared with placebo (LS mean difference,
20.62 and 20.85%, respectively; P ,
0.01); exenatide participants with BMI
.36 kg/m2 had less reduction (LS mean
difference, 20.39%; P = 0.05) (Fig. 1).
At end point, both treatment groups
had significant reductions in glucose pro-
files across the assessed baseline parameters
(Supplementary Fig. 2), with exenatide
consistently associated with significantly
lower postprandial, but not fasting, glu-
cose levels.
Change in weight
At end point, there was a weak but statis-
tically significant correlation between
weight loss andA1C reduction in exenatide
participants (R2 = 0.07; P = 0.002) and no
significant correlation for placebo (R2 =
0.002; P = 0.637). Both exenatide and pla-
cebo showed a relatively stronger, but still
weak, correlation (R2 = 0.137 and 0.144,
respectively; P , 0.001) between weight
gain and increase in insulin dose, which
was attenuated when analyzed by total
daily insulin dose, instead of change in in-
sulin dose.
Exenatide participants lost weight
during the 30-week study regardless of
baseline A1C (#8 and .8%) (Fig. 1 and
Supplementary Table 1), with significant
reductions in weight compared with pla-
cebo at end point (LS mean difference,
21.9 and 23.0 kg, respectively; P ,
0.05). Placebo participants, with baseline
A1C #8%, showed no change in weight,
while those with A1C .8% gained
weight. At study end, exenatide partici-
pants with .15 years of diabetes had
the greatest weight loss during the study
(LSmean difference at end point,23.9 kg;
Figure 1dLS mean change of A1C during 30 weeks in exenatide and placebo participants with baseline A1C#8 and.8% (A),,9, 9–15, and.15
years’ duration of diabetes (B), and baseline BMI ,30, 30–36, and .36 kg/m2 (C). LS mean change of weight during 30 weeks in exenatide and
placebo participants with baseline A1C#8 and.8% (D),,9, 9–15, and.15 years’ duration of diabetes (E), and baseline BMI,30, 30–36, and
.36 kg/m2 (F). OG+EXE, optimized insulin glargine + exenatide twice daily; OG+PBO, optimized insulin glargine + placebo. Data presented as LS
mean change in A1C and weight from baseline.
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P , 0.001). In participants with ,9
and 9–15 years of diabetes, treatment dif-
ferences were of smaller magnitude com-
pared with placebo (LS mean difference at
end point22.1 and21.9 kg, respectively;
P, 0.05). Placebo participants with.15
years of diabetes gained weight. Exenatide
participants with higher baseline BMI
(30–36 and.36 kg/m2) lost weight, while
placebo participants with baseline BMI
,30 and .36 kg/m2 gained weight.
Across baseline BMI tertiles (,30, 30–
36, and .36 kg/m2), greater weight loss
was observed in exenatide participants
compared with placebo participants (LS
mean difference, 21.5, 22.9, and 23.0
kg, respectively; P , 0.05) (Fig. 1).
Insulin dose
At end point, no treatment differences in
insulin dose with respect to baseline A1C
or duration of diabetes were observed
(Supplementary Table 1). Insulin dose was
significantly lower in exenatide participants
with baseline BMI 30–36 and .36 kg/m2
compared with placebo participants (LS
mean difference,29.2 and212.2 units, re-
spectively; P , 0.05). No difference in in-
sulin dosewas observed in participantswith
baseline BMI ,30 kg/m2 (LS mean differ-
ence at end point,21.2 units; P = 0.791).
CONCLUSIONSdIntensive basal in-
sulin replacement, with structured insu-
lin titration is often associated with
weight gain (8–12). Understanding the re-
lationships of weight changes and A1C
improvements associated with clinical
characteristics such as A1C, duration of
diabetes, and BMI may assist physicians
in individualizing specific therapies for pa-
tients with type 2 diabetes (1–4).
Higher baseline A1C is associated
with reduced ability to achieve glycemic
targets, although higher A1C values are
associated with greater reductions from
baseline (13,14). The current study dem-
onstrates the latter observation, and re-
gardless of baseline A1C, exenatide had
greater reduction relative to insulin glargine
alone.
It has been theorized that incretin-based
therapies have diminished efficacy with
long-standing disease and fewer b-cells
(15). However, the current study shows
that participants with .9 years’ duration
of diabetes had better glycemic responses
to the combination of exenatide and basal
insulin than insulin glargine alone.
Weight gain was observed in placebo
participants, while exenatide participants lost
weight at end point (5), with a significant,
but weak, correlation between A1C reduc-
tion and weight loss. Differences in weight
loss between the treatment groups seemed
to be more prominent in participants with
higher baseline A1C, higher BMI, and a
longer duration of diabetes.
This post hoc analysis must be inter-
preted cautiously. Nevertheless, these
data provide a basis to question the com-
mon perceptions that exenatide works
best in the heaviest patients with a short
duration of diabetes (15).
In summary, exenatide added to opti-
mized insulin glargine was associated with
greater A1C and weight reductions com-
pared with optimized insulin glargine
alone, including modestly obese patients
with a longer duration of diabetes.
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